Patents Examined by Jeffrey Edwin Russel
  • Neo-tryptophan
    Patent number: 7098307
    Abstract: The invention provides a novel amino acid, neo-tryptophan, as well as polypeptides containing this novel amino acid such as neurotensin analogs. In addition, the invention provides neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and polypeptides containing such derivatives. The invention also provides methods for making neo-tryptophan, neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and compositions containing these compounds. Further, the invention provides methods for inducing a neurotensin response in a mammal as well as methods for treating a mammal having a serotonin recognition molecule.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: August 29, 2006
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Elliott Richelson, Bernadette Marie Cusack, Yuan-Ping Pang, Daniel J. McCormick, Abdul Fauq, Beth Marie Tyler, Mona Boules
  • Activated polyethylene glycol esters
    Patent number: 7094872
    Abstract: The present invention relates to the preparation of polyethylene glycol carbonate active esters useful for the PEGylation of biological active and pharmaceutically useful peptides and proteins. The invention involves the use of activated carbonate and oxalate esters in the formation of polyethylene glycol mixed carbonate active esters that then react with a linker or directly with a target peptide or protein.
    Type: Grant
    Filed: February 19, 2004
    Date of Patent: August 22, 2006
    Assignee: Pharmacia Corporation
    Inventor: Foe S. Tjoeng
  • Fibrin/fibrinogen-binding conjugate
    Patent number: 7091325
    Abstract: A fibrin/fibrinogen binding conjugate for forming a depot for the sustained release of a pharmaceutically active substance from a fibrin clot. The conjugate comprises a fibrin/fibrinogen binding moiety bound to a pharmaceutically active substance either directly or via an intervening substance capturing moiety such as an antibody. The conjugate can also be a recombinant fusion protein comprising a fibrin/fibrinogen binding moiety such as VEGF165 C-terminal domain fused to a wound-healing substance such as leptin.
    Type: Grant
    Filed: December 30, 2003
    Date of Patent: August 15, 2006
    Assignees: Baxter Aktiengesellschaft, Baxter International Inc.
    Inventors: Heinz Redl, Walter Fuerst, Rudolf Kneidinger, Sam L. Helgerson, Douglas Looker, Elisabeth M. Inman, Jane P. Richards, Catalina Wong
  • Method for preparing polycation based bioconjugates suitable for transporting different kinds of active substances within the body
    Patent number: 7090846
    Abstract: Polycation bioconjugates and a method for producing them. The polycations are capable of transporting active substances of different types. The polycations function as carrier molecules that transport enhancer molecules, thereby enhancing the biological effectiveness of the transported molecules. The polycation bioconjugates of the present invention may inhibit malignant cell proliferation, possess antimicrobial effect, or be configured for gene transport.
    Type: Grant
    Filed: February 23, 2004
    Date of Patent: August 15, 2006
    Assignee: Refuah Research, Inc.
    Inventor: Peter Szego
  • Method of promoting natural bypass
    Patent number: 7087577
    Abstract: An angiogenic factor comprising a mixture of proteins derived from bone. The angiogenic protein mixture is produced by a series of steps that allow the proteins to be kept in solution. The angiogenic mixture of bone proteins is produced by a multi-step process that includes at least one ultrafiltration step, an anion exchange chromatography step, a cation exchange chromatography step and a high performance liquid chromatography (HPLC) purification step.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: August 8, 2006
    Assignee: Zimmer OrthoBiologies, Inc.
    Inventors: James J. Benedict, John P. Ranieri, Marsha L. Whitney, Rama Akella
  • Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
    Patent number: 7084121
    Abstract: A mixture of conjugates in which each conjugate in the mixture comprises a calcitonin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may lower serum calcium levels in a subject by 10, 15 or even 20 percent or more. Moreover, the mixture may be more effective at surviving an in vitro model of intestinal digestion than non-conjugated calcitonin. Furthermore, the mixture may exhibit a higher bioavailability than non-conjugated calcitonin.
    Type: Grant
    Filed: March 23, 2004
    Date of Patent: August 1, 2006
    Assignee: Nobex Corporation
    Inventors: Nnochiri N. Ekwuribe, Christopher H. Price, Aslam M. Ansari, Amy L. Odenbaugh
  • Mixtures of insulin drug-oligomer comprising polyalkylene glycol
    Patent number: 7084114
    Abstract: A mixture of conjugates in which each conjugate in the mixture comprises an insulin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugates. The mixture may also be more effective at surviving an in vitro model of intestinal digestion than polydispersed mixtures of similar conjugates. The mixture may also result in less inter-subject variability than polydispersed mixtures of similar conjugates.
    Type: Grant
    Filed: April 29, 2004
    Date of Patent: August 1, 2006
    Assignee: Nobex Corporation
    Inventors: Nnochiri N. Ekwuribe, Christopher H. Price, Aslam M. Ansari, Balasingam Radhakrishnan, Amy L. Odenbaugh
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Patent number: 7084108
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: August 1, 2006
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
    Patent number: 7084117
    Abstract: The present invention relates to a method of treating vascular proliferation in a patient in need thereof. The method includes the step of administering a therapeutically effective amount of a type-1 somatostatin agonist to said patient.
    Type: Grant
    Filed: January 14, 2002
    Date of Patent: August 1, 2006
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, SAS
    Inventors: Michael Dewitt Culler, Romano Danesi, Guido Bocci, Mario Deltacca
  • Cyclosporin galenic forms
    Patent number: 7081445
    Abstract: Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.
    Type: Grant
    Filed: March 1, 2004
    Date of Patent: July 25, 2006
    Assignee: Novartis AG
    Inventors: Thomas Cavanak, Ulrich Posanski
  • Method of regulating glucose metabolism, and reagents related thereto
    Patent number: 7078381
    Abstract: The present invention provides methods and compositions for modifying glucose metabolism and treating Type II diabetes in an animal, along with modifying metabolism of a peptide hormone in an animal. Compositions disclosed herein comprise one or more peptides and/or peptide analogs which include a functional group that reacts with an active site residue of a protease.
    Type: Grant
    Filed: March 4, 2004
    Date of Patent: July 18, 2006
    Assignee: Trustees of Tufts College
    Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel Drucker
  • Synthetic peptide analogs of Arg-Pro-Pro-Gly-Phe as selective inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4
    Patent number: 7074765
    Abstract: The invention relates to compounds and methods for inhibiting human platelet aggregation, thrombosis and cell activation mediated by PAR1 and PAR4 using peptide analogs of Arg-Pro-Pro-Gly-Phe that contain one or more amino acid substitutions. The invention also includes screening methods for identifying compounds that inhibit thrombin mediated activities.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: July 11, 2006
    Assignees: The Regents of the University of Michigan, Thromgen, Inc.
    Inventors: Alvin H. Schmaier, Ahmed A. K. Hasan
  • Method of modifying the release profile of sustained release compositions
    Patent number: 7074432
    Abstract: The present invention relates to a method for the sustained release in vivo of a biologically active agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active agent incorporated therein, and a bisphosphonate wherein the bisphosphonate compound is present in an amount sufficient to modify the release profile of the biologically active agent from the sustained release composition. Pharmaceutical compositions suitable for use in the method of the invention are also disclosed.
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: July 11, 2006
    Assignee: Alkermes Controlled Therapeutics, Inc.
    Inventors: James R. Dasch, M. Gary I. Riley
  • Treatment of case-ready food products with immobilized lactoferrin (Im-LF) and the products so produced
    Patent number: 7074759
    Abstract: Disclosed is a method for reducing the microbial contamination in products, such as case-ready meat products, including ready-to-eat meat products, subject to microbial contamination, including contamination by E. coli and Listeria monocytogenes. The food products are treated with a defined dispersion of lactoferrin immobilized on a naturally occurring substrate via the N-terminus region of the lactoferrin. Also disclosed are case-ready food products, including ready-to-eat food products, prepared in accordance with such a method.
    Type: Grant
    Filed: June 23, 2003
    Date of Patent: July 11, 2006
    Inventor: A. Satyanarayan Naidu
  • Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
    Patent number: 7071167
    Abstract: Disclosed herein is a composition for topical application to skin, comprising, in a physiologically acceptable medium (i) at least one peptide comprising at least one amino acid sequence derived from the amino acid sequence of the protein SNAP 25, and (ii) at least one calcium-channel inhibitor. Further disclosed is the use of this combination in a composition suitable for topical application to the skin, as an agent for preventing or treating wrinkles and fine lines, such as expression wrinkles, as well as a cosmetic treatment process comprising applying to the skin the composition.
    Type: Grant
    Filed: November 13, 2003
    Date of Patent: July 4, 2006
    Assignee: L'Oreal
    Inventor: Béatrice Renault
  • Hematopoietic stimulation
    Patent number: 7067489
    Abstract: Methods and products for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells are provided. The methods and products can be used both in vivo and in vitro. The methods involve administering an agent of Formula I wherein m is an integer between 0 and 10, inclusive; A and A1 are L-amino acid residues such that the A in each repeating bracketed unit can be the same or a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A1 and C, and between A1 and N are peptide bonds; and each X1 and X2 is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH. The products include kits comprising the agent of Formula I.
    Type: Grant
    Filed: June 28, 2004
    Date of Patent: June 27, 2006
    Assignee: Point Therapeutics, Inc.
    Inventors: Barbara P. Wallner, Barry Jones, Glenn T. Miller, Sharlene Adams
  • Peptide substrates of a proteolytic ADAM33 polypeptide and assays using the same
    Patent number: 7067273
    Abstract: The present invention discloses peptide substrates of a proteolytic ADAM33 polypeptide. The present invention also discloses methods of identifying additional substrates of a proteolytic ADAM33 polypeptide. Furthermore, the present invention discloses methods of identifying compounds that inhibit the proteolytic activity of a proteolytic ADAM33 polypeptide.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: June 27, 2006
    Assignee: Schering Corporation
    Inventors: Rumin Zhang, Jun Zou, Feng X. Zhu, James P. Durkin, William T. Windsor, Shelby P. Umland
  • Compounds and compositions for delivering active agents
    Patent number: 7067119
    Abstract: Modified amino acid compounds useful in the delivery of active agents are provided. The active agents can be peptides. Methods of administration, such as oral, subcutaneous, sublingual, and intranasal administration and methods of preparation of the modified amino acid compounds are also provided.
    Type: Grant
    Filed: July 9, 2003
    Date of Patent: June 27, 2006
    Assignee: Emisphere Technologies, Inc.
    Inventors: Andrea Leone-Bay, Koc-Kan Ho, Donald J. Sarubbi, Sam J. Milstein
  • Hepta-, Octa-and nonapeptides having antiangiogenic activity
    Patent number: 7067490
    Abstract: Compounds of formula (SEQ ID NO:1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: June 27, 2006
    Assignee: Abbott Laboratories
    Inventors: Fortuna Haviv, Michael F. Bradley
  • Compounds and methods for inhibiting the interaction between ?-catenin and ?-catenin
    Patent number: 7063842
    Abstract: Modulating agents for inhibiting an interaction between ?-catenin and ?-catenin are provided. The modulating agents comprise one or more of: (a) a ?-catenin HAV motif; (b) a peptide analogue or mimetic of a ?-catenin HAV motif; or (c) an antibody or antigen-binding fragment thereof that specifically binds to a ?-catenin HAV motif. Methods for using such modulating agents for inhibiting cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: June 20, 2006
    Assignee: McGill University
    Inventors: Orest W Blaschuk, Barbara J Gour